tiprankstipranks
Trending News
More News >
Nu Skin Enterprises (NUS)
NYSE:NUS
Advertisement

Nu Skin (NUS) AI Stock Analysis

Compare
459 Followers

Top Page

NUS

Nu Skin

(NYSE:NUS)

Select Model
Select Model
Select Model
Outperform 78 (OpenAI - 4o)
Rating:78Outperform
Price Target:
$14.50
▲(18.46% Upside)
Nu Skin's overall stock score is driven by strong technical indicators and a positive earnings call, highlighting growth and operational efficiency. While financial performance shows some challenges, the attractive valuation and strategic innovations provide a positive outlook.
Positive Factors
Operational Efficiency
Strong cost management and operational efficiency have allowed Nu Skin to exceed earnings expectations, indicating robust internal controls and a focus on profitability, which can sustain long-term growth.
Latin America Growth
The substantial growth in Latin America showcases Nu Skin's ability to penetrate and expand in emerging markets, providing a strong foundation for future revenue streams and market diversification.
Innovation with Prysm iO
Prysm iO represents a strategic innovation that can enhance customer engagement and product differentiation, positioning Nu Skin as a leader in personalized wellness solutions.
Negative Factors
Revenue Decline
The decline in revenue growth indicates potential challenges in maintaining market share and sales momentum, which could impact long-term financial performance and strategic objectives.
Negative Free Cash Flow
Negative free cash flow trends suggest difficulties in generating sufficient cash to fund operations and investments, potentially limiting Nu Skin's ability to capitalize on growth opportunities.
Challenges in North America
Macroeconomic pressures in North America pose a risk to Nu Skin's revenue and profitability, highlighting the need for strategic adjustments to mitigate regional economic impacts.

Nu Skin (NUS) vs. SPDR S&P 500 ETF (SPY)

Nu Skin Business Overview & Revenue Model

Company DescriptionNu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
How the Company Makes MoneyNu Skin generates revenue primarily through the sale of its products to consumers via its network of independent distributors. The company employs a multi-level marketing (MLM) strategy, which allows distributors to earn commissions not only on their sales but also on the sales made by their recruits. This creates a tiered earning structure that incentivizes recruitment and sales. Key revenue streams include skincare and beauty products, dietary supplements, and personal care items, with a significant portion of sales originating from markets in Asia and North America. Partnerships with various health and wellness organizations, as well as investments in product innovation and technology, further enhance Nu Skin's market presence and contribute to its overall earnings.

Nu Skin Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 29, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong financial performance with revenue and earnings surpassing expectations, significant growth in Latin America, and successful cost management initiatives. However, challenges remain in North America and the Asian markets, with some decline in gross margin. The overall sentiment is bolstered by promising innovations like Prysm iO and financial stability, resulting in a positive outlook.
Q2-2025 Updates
Positive Updates
Revenue and Earnings Exceed Expectations
Nu Skin delivered revenue of $386.1 million, at the high end of its guidance range, and significantly exceeded its earnings per share forecast with $0.43, above the guidance range of $0.20 to $0.30, showcasing strong cost management and operational efficiency.
Latin America Market Success
Latin America demonstrated remarkable performance with more than 100% year-over-year growth in revenue, customers, and sales leaders, driven by a simplified and focused business model.
Project Accelerate and Margin Expansion
Project Accelerate led to an operating margin increase to 8%, driven by improvements in gross margin, selling expense alignment, and G&A cost reductions.
Positive Cash Flow and Debt Position
The company generated $35.8 million in cash flow from operations, achieving a net cash positive position for the first time in over four years, providing greater financial flexibility.
Rhyz Segment and Manufacturing Growth
Rhyz segments performed well, with manufacturing reporting a 17% year-over-year increase, contributing to speed to market for new products.
Innovation with Prysm iO
The introduction of Prysm iO, an intelligent wellness platform leveraging AI and a vast antioxidant database, is expected to bring personalized health insights and product recommendations to consumers.
Negative Updates
Declines in North America
North America faced increasing macroeconomic pressures, which negatively impacted the business performance in the region.
Economic Challenges in South Korea and China
Revenue in South Korea and China declined due to persistent economic challenges, although there are signs of sequential improvement.
Gross Margin Decline
The Q2 gross margin was 68.8%, down from 70% in the prior year, primarily due to changes in revenue mix following the sale of Mavely.
Company Guidance
In the Q2 2025 Nu Skin Enterprises earnings call, the company reported revenue of $386.1 million, reaching the high end of their guidance range, and an earnings per share (EPS) of $0.43, significantly exceeding the forecasted range of $0.20 to $0.30. This was attributed to disciplined cost management and operational efficiencies. The company highlighted strong growth in Latin America with over 100% year-over-year revenue increase, while North America experienced declines due to macroeconomic pressures. Japan showed growth, benefiting from a strong subscription-based wellness business, although revenue in South Korea and China declined. Nu Skin announced plans to launch their new wellness platform, Prysm iO, globally in 2026, and reported a 17% year-over-year growth in their Rhyz manufacturing segment. The company aims to improve gross margins to 78% and anticipates a net cash-positive position, enhancing flexibility for future investments. Guidance for Q3 2025 projects revenue between $360 million and $390 million, with EPS expected to range from $0.25 to $0.35.

Nu Skin Financial Statement Overview

Summary
Nu Skin is facing financial headwinds with declining revenues and profitability impacting both its income statement and balance sheet. While cash flow remains positive, the company needs to improve operational efficiency and profitability to strengthen its financial position. The balance sheet is moderately leveraged, providing some financial stability, but the company must focus on reversing its negative profitability trend.
Income Statement
65
Positive
Nu Skin has experienced declining revenue and profitability over the recent periods. The TTM revenue is down from previous years, and net income has turned negative. Gross profit margin remains relatively stable, but the net profit margin has deteriorated due to negative EBIT and EBITDA. The company needs to address its operational inefficiencies to return to profitability.
Balance Sheet
70
Positive
The balance sheet shows a moderate debt-to-equity ratio, indicating a balanced approach to leveraging. However, the decline in stockholders' equity and total assets is concerning. Return on equity has turned negative, reflecting poor profitability. The equity ratio remains stable, suggesting a decent level of financial stability despite recent challenges.
Cash Flow
60
Neutral
Nu Skin's cash flow situation is relatively stable, with positive free cash flow and operating cash flow. However, the growth in free cash flow is limited, and the company has faced challenges in translating its cash flow into net income. Continued positive cash flow is a positive sign, but improvements in profitability are needed for long-term stability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.63B1.73B1.97B2.23B2.70B2.58B
Gross Profit1.09B1.18B1.36B1.62B2.02B1.92B
EBITDA196.71M-78.83M202.98M231.85M368.48M331.56M
Net Income100.83M-146.59M8.60M104.78M147.27M191.35M
Balance Sheet
Total Assets1.44B1.47B1.81B1.82B1.91B1.96B
Cash, Cash Equivalents and Short-Term Investments264.16M197.99M267.82M278.51M354.81M423.90M
Total Debt310.74M478.23M607.33M520.52M503.79M500.38M
Total Liabilities655.94M817.46M984.50M923.67M993.71M1.06B
Stockholders Equity787.75M651.46M821.97M897.30M912.77M894.27M
Cash Flow
Free Cash Flow58.62M70.16M60.15M49.01M72.97M315.32M
Operating Cash Flow93.40M111.74M118.64M108.06M141.58M379.14M
Investing Cash Flow170.17M-37.96M-134.50M-67.08M-88.73M-79.43M
Financing Cash Flow-229.43M-133.18M10.73M-99.50M-104.70M-245.17M

Nu Skin Technical Analysis

Technical Analysis Sentiment
Positive
Last Price12.24
Price Trends
50DMA
10.80
Positive
100DMA
9.33
Positive
200DMA
8.09
Positive
Market Momentum
MACD
0.34
Positive
RSI
57.06
Neutral
STOCH
17.20
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUS, the sentiment is Positive. The current price of 12.24 is above the 20-day moving average (MA) of 11.98, above the 50-day MA of 10.80, and above the 200-day MA of 8.09, indicating a bullish trend. The MACD of 0.34 indicates Positive momentum. The RSI at 57.06 is Neutral, neither overbought nor oversold. The STOCH value of 17.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NUS.

Nu Skin Risk Analysis

Nu Skin disclosed 12 risk factors in its most recent earnings report. Nu Skin reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Nu Skin Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$605.85M5.9913.68%2.00%-11.79%
70
Outperform
17.35B57.469.43%0.54%23.05%-32.01%
69
Neutral
13.20B73.0934.41%88.69%947.74%
52
Neutral
583.98M-1.75-27.14%-4.39%-326.42%
50
Neutral
249.85M-7.00-56.17%-15.33%75.52%
47
Neutral
3.50B-9.17-9.98%-3.68%-631.67%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NUS
Nu Skin
12.24
5.07
70.71%
HELE
Helen Of Troy
25.44
-36.41
-58.87%
SGI
Somnigroup International
82.64
28.53
52.73%
COTY
Coty
4.01
-5.38
-57.29%
HIMS
Hims & Hers Health
58.40
39.98
217.05%
SKIN
Beauty Health
1.97
0.53
36.81%

Nu Skin Corporate Events

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Nu Skin Approves 2024 Incentive Plan at Annual Meeting
Positive
May 30, 2025

On May 29, 2025, Nu Skin Enterprises held its Annual Meeting of Stockholders, where the stockholders approved the Amended and Restated 2024 Omnibus Incentive Plan. This plan increases the share authorization by 790,000 shares, clarifies the vesting of performance cash awards, and extends the termination date to May 29, 2035. Additionally, the meeting saw the election of nine directors, advisory approval of executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025. These decisions are expected to impact Nu Skin’s operational strategies and governance structure positively.

The most recent analyst rating on (NUS) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Nu Skin stock, see the NUS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 23, 2025